Inanovate, Inc
Overview
Inanovate has developed a patented blood analysis system for use in research and clinical diagnostics applications. The system, called the Bio-ID, is enabling a new generation of advanced diagnostics through the accurate measurement of a near unlimited range of disease related biological molecules in one low-cost easy to use blood test.
Inanovate’s first diagnostic application of the Bio-ID platform is a low-cost blood test to monitor for breast cancer recurrence, being developed in partnership with Sanford Health. Inanovate is presently raising $1.25million in investment capital to advance the breast cancer test through the next phase of clinical trials.